Medical Devices Risk to Tackle Coronavirus

Please join our first webcast, Medical Devices Risk to Tackle Coronavirus, as part of our series that will offer guidance to understand how to navigate and manage the potential risks that come with producing medical devices.

As COVID-19 developments increase at a rapid rate globally, the concern about the lack of life-saving equipment and other essential supplies to prevent the spread of the virus and care for the sick are also rapidly increasing.

More broadly, there is urgent need to escalate the manufacturing of a full range of medical devices, such as face masks, ventilators and test kits (self-administered, antibody tests). To help meet needs during this crisis, governments are now turning to the private sector for assistance, not just in physical manufacturing but also for capabilities in design, procurement, assembly, testing and shipping.

Schedule 4:00 p.m. – 4:45 p.m. BST (11 a.m. – 11:45 a.m. EST)

Register now.

Key Takeaways

Identifying supplier credibility:

• Uncertainty over which suppliers can produce equipment of the right quality, at the right production volume, at the right time

• Lack of understanding a new industry to work within (ie. retail to medical device industry) can create opportunity for credibility risk

Transportation:

• Transport tracking options need to be validated to ensure the right shipments can move from factories to airports to distribution centers to health centers around the world, under the right conditions (e.g., temperature controlled for pharmaceutical products)

• Exposure to risks in working within a new industry and new vendors

Third-party commercial representation: 

• Corruption in the medical industry can range vastly from bribing a doctor to prescribe medicine irrespective of a health need, to a government employee facilitating the infiltration of substandard medicines into the distribution system for kickbacks

• Global scramble for vital items has exposed the harsh realities of international politics and the limits of the freed market 

Speakers

• Thomas Hollobone, Associate Managing Director, Compliance Risk and Diligence,
  Kroll, a division of Duff & Phelps

• Andreas Chrystomou, Managing Director, Valuation Services,
  Global Healthcare and Life Sciences Industry Leader, Duff & Phelps

• Roeland Van Aelst, EMEA Lead Third Party Intermediary Ethics and Compliance, 
  Johnson & Johnson, Chairman, International Society of Healthcare, Ethics and Compliance Professionals (ETHICS), Chairman, MedTech Europe Code Committee

We look forward to your attendance. Click here to register for this webinar.